MindMed, a Silicon Valley Startup, Tests Psychedelics to Treat Addiction

[ad_1]

Psychedelic medicine is hot right now—or regulatory agencies seem to be warming up to the idea, at least. Over the last few years, the FDA has begun to approve (and even fast-track) clinical trials examining the impact of substances like ketamine, psilocybin, and MDMA on mental health issues like post-traumatic stress disorder and major depressive disorder. In addition to contributing to the growing ...

Continue Reading →
UA-77446339-1